<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092168</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-105</org_study_id>
    <nct_id>NCT02092168</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects</brief_title>
  <official_title>Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of age on the pharmacokinetic (PK)&#xD;
      profile of BIA 9-1067 and its metabolites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      Single-centre, open-label, parallel group, non-randomised multiple-dose 7-day study in 12&#xD;
      healthy elderly and 12 healthy younger male subjects.&#xD;
&#xD;
      Duration of treatment:&#xD;
&#xD;
      Each subject participated in the study for approximately 6 weeks. Participation included a&#xD;
      screening evaluation within 28 days before inpatient period, a 12 day inpatient period and an&#xD;
      end of study visit (ESV) 7 to 10 days after the discharge from the Unit.&#xD;
&#xD;
      The study design followed the recommendations of the CPMP/ICH/379/95 (ICH Topic E7) Note for&#xD;
      Guidance on Studies in Support of Special Populations: Geriatrics, namely in the inclusion of&#xD;
      subjects aged 65 years or older and contemplating single-dose and steady-state PK profiles.&#xD;
      As the primary endpoint of the study was to characterize the pharmacokinetic profile of BIA&#xD;
      9-1067 and its metabolites in different parallel groups, there was no need to implement&#xD;
      blinding procedures or to include a control group. Consequently, the trial was an open label&#xD;
      study. Healthy subjects rather than patients with Parkinson's disease have been chosen as the&#xD;
      study population, due to the lack of over-toxicity of the drug and an acceptable risk-benefit&#xD;
      ratio. This allowed for a better interpretation of the study results, as there were no&#xD;
      confounding factors resulting from changes in disease state and or concomitant medications.&#xD;
&#xD;
      The subjects were given a screening number after signing the informed consent by&#xD;
      chronological order of inclusion in each group (young/elderly).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Reach Cmax</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Elderly Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Young Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Elderly Subjects</arm_group_label>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Young Subjects</arm_group_label>
    <other_name>Opicapone, OPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects (young and elderly):&#xD;
&#xD;
          1. A signed and dated informed consent form before any study-specific screening procedure&#xD;
             is performed.&#xD;
&#xD;
          2. Healthy as determined by the investigator on the basis of medical history, physical&#xD;
             examination, clinical laboratory test results, vital signs and digital 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          3. Non-smoker or smoker of fewer than 10 cigarettes per day as determined by history. Had&#xD;
             to be able to abstain from smoking during the inpatient stay.&#xD;
&#xD;
          4. With a body mass index (BMI) between 19 and 30 kg/m2, inclusive.&#xD;
&#xD;
             Young subjects only:&#xD;
&#xD;
          5. Males aged between 18 and 40 years, inclusive.&#xD;
&#xD;
             Elderly subjects only:&#xD;
&#xD;
          6. Males older than 65 years, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects (young and elderly):&#xD;
&#xD;
        General&#xD;
&#xD;
          1. Subjects who had participated in a clinical trial with an investigational drug within&#xD;
             the 90 days prior to screening.&#xD;
&#xD;
          2. Subjects who were likely to be noncompliant with the protocol, or who were felt to be&#xD;
             unsuitable by the Investigator for any other reason.&#xD;
&#xD;
          3. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.&#xD;
&#xD;
          4. Positive findings of urine drug screen (amphetamines, barbiturates, benzodiazepines,&#xD;
             cannabinoids, cocaine, methadone, opiates, MDMA [3,4-ethylenedioxymethamphetamine;&#xD;
             ecstasy]).&#xD;
&#xD;
             Medical History&#xD;
&#xD;
          5. Any significant cardiovascular, hepatic, renal, respiratory (e.g. childhood asthma),&#xD;
             gastrointestinal, endocrine (e.g. diabetes,), immunological, dermatological,&#xD;
             haematological, neurological, or psychiatric disease and history thereof.&#xD;
&#xD;
          6. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before&#xD;
             study Day 1.&#xD;
&#xD;
          7. History of drug abuse within 1 year before study Day 1.&#xD;
&#xD;
          8. History of alcoholism within 1 year before Day 1. Consumption of more than 50 g of&#xD;
             ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%]&#xD;
             whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15&#xD;
             g).&#xD;
&#xD;
          9. History of any clinically important drug allergy.&#xD;
&#xD;
         10. Had previously received BIA 9-1067.&#xD;
&#xD;
             Prohibited treatments and dietary restrictions&#xD;
&#xD;
         11. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or&#xD;
             soda) in excess of 6 cups per day (or equivalent), of grapefruit,&#xD;
             grapefruit-containing products, or alcoholic beverages within 24 hours before study&#xD;
             Day 1.&#xD;
&#xD;
         12. Use of any over-the-counter drugs including herbal supplements (except for the&#xD;
             occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended&#xD;
             daily allowance) within 7 days before IMP administration.&#xD;
&#xD;
         13. Donation of blood (i.e. 450 ml) within 60 days before study Day 1.&#xD;
&#xD;
             Young subjects only:&#xD;
&#xD;
             Prohibited treatments and dietary restrictions&#xD;
&#xD;
         14. Prohibited Treatments: use of any investigational drug within 90 days (young and&#xD;
             elderly subjects) or prescription drug within 30 days before investigational medical&#xD;
             product (IMP) administration.&#xD;
&#xD;
             Elderly subjects only:&#xD;
&#xD;
             Prohibited treatments and dietary restrictions&#xD;
&#xD;
         15. For elderly subjects, previously prescribed medications that do not interfere with&#xD;
             absorption, distribution, metabolism, and excretion or safety/tolerability evaluation&#xD;
             of BIA 9-1067 and adrenal or renal function were allowed if the dose regimen had been&#xD;
             stable for at least 4 weeks and was expected to remain stable throughout the study.&#xD;
             Such concomitant medications was reviewed and mutually agreed upon by the sponsor and&#xD;
             the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrício SOARES-DA-SILVA, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BIAL - Portela &amp; Ca S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOTRIAL</name>
      <address>
        <city>Rueil</city>
        <state>Malmaison</state>
        <zip>F-92501</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <results_first_submitted>January 7, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opicapone</keyword>
  <keyword>BIAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 30 mg (QD) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (QD) - Elderly Subjects</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 30 mg (QD) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (QD) - Young Subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration</title>
        <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Plasma Concentration</title>
          <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.4" spread="81.1"/>
                    <measurement group_id="O2" value="391.1" spread="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.6" spread="127.5"/>
                    <measurement group_id="O2" value="382.0" spread="146.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Reach Cmax</title>
        <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Reach Cmax</title>
          <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</title>
        <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</title>
          <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1265.9" spread="240.6"/>
                    <measurement group_id="O2" value="1204.1" spread="474.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1413.65" spread="451.3"/>
                    <measurement group_id="O2" value="1112.3" spread="338.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.&#xD;
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial - Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

